Flora Peyvandi / X
Jun 25, 2025, 15:23
Is the Glanzmann Era Finally Over? Flora Peyvandi on Latest Bispecific Antibodies: ISTH 2025
Flora Peyvandi, Professor of Internal Medicine at the University of Milan and former President of ISTH, shared a post on X:
”How to solve the problem of patients with Glanzmann using a novel bispecific abs – ISTH2025”
So, has the Glanzmann era truly ended—or is it just taking a coffee break before staging a comeback?
Sutacimig, a novel bispecific antibody with dual binding of FVIIa and TLT-1, seems to actually resolve the issues with clot formation in Glanzmann!
More of the latest ISTH2025 news to be posted on Hemostasis Today.
-
Sep 30, 2026, 15:58Bernhard Merget: New Frontiers in Thrombosis and Stroke Research
-
Sep 30, 2026, 15:39Ifeanyichukwu Ifechidere: The Molecular Orchestra of Primary Hemostasis
-
Sep 30, 2026, 15:28Reassessing the Benefit–Risk Balance of Extended Anticoagulation in Cancer Patients – ESC Working Group on Cardiovascular Pharmacotherapy
-
Sep 30, 2026, 15:07Chiranjeev Sharma: Targeting Factor XIa with the Synthetic Inhibitor SB-01
-
Sep 30, 2026, 14:41Bruna Gigante: Balancing Thrombosis and Bleeding in Cardiovascular Care
-
Sep 30, 2026, 14:13Ashok Choudhury: Portal Vein Thrombosis and Outcomes in Cirrhosis
-
Sep 30, 2026, 13:57Leslye Conde Bazán: When Conventional Imaging Is Not Enough – The Role of IVUS
-
Sep 30, 2026, 13:41Huda Salah Eldin: The Challenge of Balancing Antithrombotic Therapy After PCI
-
Sep 30, 2026, 13:29Abdus Salam: What Can CT Venography Reveal About the Veins?